Article Data

  • Views 842
  • Dowloads 163

Systematic reviews

Open Access

Anakinra for patients with COVID-19: an updated systematic review and meta-analysis

  • Giulio Cavalli1
  • Paolo Navalesi2,3
  • Giovanni Landoni4,5,*,
  • Andrey G. Yavorovskiy6
  • Valery V. Likhvantsev6,7
  • Alberto Zangrillo4,5
  • Lorenzo Dagna1,5
  • Giacomo Monti4,5
  • Laura Pasin2

1Unit of Immunology, Rheumatology, Allergy, and Rare Diseases, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy

2Institute of Anesthesia and Intensive Care, Azienda Ospedale-Università di Padova, 35128 Padova, Italy

3Department of Medicine (DIMED), University of Padova, 35128 Padova, Italy

4Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy

5Faculty of Medicine, Vita-Salute San Raffaele University, 20132 Milan, Italy

6I.M. Sechenov First Moscow State Medical University, Ministry of Public Health of Russia, 119991 Moscow, Russia

7V. Negovsky Reanimatology Research Institute, 107031 Moscow, Russia

DOI: 10.22514/sv.2023.025

Submitted: 18 August 2022 Accepted: 20 October 2022

Online publish date: 13 April 2023

*Corresponding Author(s): Giovanni Landoni E-mail: landoni.giovanni@hsr.it

Abstract

Severe COVID-19 patients can develop a maladaptive immune response with hyper-production of cytokines and chemokines which lead to alveolar damage, endothelial activation, coagulopathy and thromboembolic events. We performed a meta-analysis which included any study performed on COVID-19 patients with respiratory hypoxemic failure who received anakinra versus any comparator. Primary endpoint was mortality. Secondary endpoints were intubation rate, superinfection and thromboembolic events. Subgroups analyses included patients in general ward, with hyperinflammation and/or baseline ratio of arterial oxygen partial pressure (PaO2) to fractional inspired oxygen (FiO2) >200. Twenty-four studies were included. Mortality in anakinra patients was significantly lower than mortality of controls (19% vs. 28%; p < 0.0001). Anakinra patients had significantly lower risk of intubation (16% vs. 33%; p < 0.001). Mortality reduction was confirmed in general ward settings, in patients with hyperinflammation and with PaO2/FiO2 >200, but not when selecting randomized studies only. A trend towards increased mortality in more severe patients was observed.


Keywords

Anakinra; COVID-19; SARS-CoV-2; Meta-analysis; Mortality


Cite and Share

Giulio Cavalli,Paolo Navalesi,Giovanni Landoni,Andrey G. Yavorovskiy,Valery V. Likhvantsev,Alberto Zangrillo,Lorenzo Dagna,Giacomo Monti,Laura Pasin. Anakinra for patients with COVID-19: an updated systematic review and meta-analysis. Signa Vitae. 2023.doi:10.22514/sv.2023.025.

References

[1] World Health Organization. WHO Coronavirus (COVID-19) Dashboard With Vaccination Data. 2022. Available at: https://covid19.who. int/ (Accessed: 16 August 2021).

[2] Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020; 395: 1033–1034.

[3] Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020; 395: 1417–1418.

[4] Campochiaro C, Della-Torre E, Cavalli G, De Luca G, Ripa M, Boffini N, et al. Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study. European Journal of Internal Medicine. 2020; 76: 43–49.

[5] De Luca G, Cavalli G, Campochiaro C, Della-Torre E, Angelillo P, Tomelleri A, et al. GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study. The Lancet. Rheumatology. 2020; 2: e465–e473.

[6] Della-Torre E, Campochiaro C, Cavalli G, De Luca G, Napolitano A, La Marca S, et al. Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study. Annals of the Rheumatic Diseases. 2020; 79: 1277–1285.

[7] Cavalli G, Farina N, Campochiaro C, De Luca G, Della-Torre E, Tomelleri A, et al. Repurposing of biologic and targeted synthetic anti-rheumatic drugs in COVID-19 and hyper-inflammation: a comprehensive review of available and emerging evidence at the peak of the pandemic. Frontiers in Pharmacology. 2020; 11: 598308.

[8] Rodrigues TS, de Sá KSG, Ishimoto AY, Becerra A, Oliveira S, Almeida L, et al. Inflammasomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients. The Journal of Experimental Medicine. 2021; 218: e20201707.

[9] Cavalli G, Dinarello CA. Anakinra therapy for non-cancer inflammatory diseases. Frontiers in Pharmacology. 2018; 9: 1157.

[10] Cavalli G, Colafrancesco S, Emmi G, Imazio M, Lopalco G, Maggio MC, et al. Interleukin 1α: a comprehensive review on the role of IL-1α in the pathogenesis and treatment of autoimmune and inflammatory diseases. Autoimmunity Reviews. 2021; 20: 102763.

[11] Shakoory B, Carcillo JA, Chatham WW, Amdur RL, Zhao H, Dinarello CA, et al. Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase III trial. Critical Care Medicine. 2016; 44: 275–281.

[12] Strati P, Ahmed S, Kebriaei P, Nastoupil LJ, Claussen CM, Watson G, et al. Clinical efficacy of anakinra to mitigate CAR T-cell therapy-associated toxicity in large B-cell lymphoma. Blood Advances. 2020; 4: 3123–3127.

[13] Navarro-Millán I, Sattui SE, Lakhanpal A, Zisa D, Siegel CH, Crow MK. Use of anakinra to prevent mechanical ventilation in severe COVID-19: a case series. Arthritis & Rheumatology. 2020; 72: 1990–1997.

[14] Pontali E, Volpi S, Antonucci G, Castellaneta M, Buzzi D, Tricerri F, et al. Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung disease. The Journal of Allergy and Clinical Immunology. 2020; 146: 213–215.

[15] Aouba A, Baldolli A, Geffray L, Verdon R, Bergot E, Martin-Silva N, et al. Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series. Annals of the Rheumatic Diseases. 2020; 79: 1381–1382.

[16] Dimopoulos G, de Mast Q, Markou N, Theodorakopoulou M, Komnos A, Mouktaroudi M, et al. Favorable anakinra responses in severe Covid-19 patients with secondary hemophagocytic lymphohistiocytosis. Cell Host & Microbe. 2020; 28: 117–123.

[17] Cavalli G, De Luca G, Campochiaro C, Della-Torre E, Ripa M, Canetti D, et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. The Lancet Rheumatology. 2020; 2: e325–e331.

[18] Cavalli G, Larcher A, Tomelleri A, Campochiaro C, Della-Torre E, De Luca G, et al. Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study. The Lancet Rheumatology. 2021; 3: e253–e261.

[19] Pasin L, Cavalli G, Navalesi P, Sella N, Landoni G, Yavorovskiy AG, et al. Anakinra for patients with COVID-19: a meta-analysis of non-randomized cohort studies. European Journal of Internal Medicine. 2021; 86: 34–40.

[20] Kyriazopoulou E, Poulakou G, Milionis H, Metallidis S, Adamis G, Tsiakos K, et al. Early anakinra treatment for COVID-19 guided by urokinase plasminogen receptor. medRxiv. 2021; 1–32.

[21] CORIMUNO-19 Collaborative group. Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial. The Lancet. Respiratory Medicine. 2021; 9: 295–304.

[22] Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016; 355: i4919.

[23] Higgins JPT, Thomas J. Cochrane Handbook for Systematic Reviews of Interventions. 2nd edn. Wiley-Blackwell: USA. 2019.

[24] Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019; 366: l4898.

[25] Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009; 339: b2700.

[26] Huet T, Beaussier H, Voisin O, Jouveshomme S, Dauriat G, Lazareth I, et al. Anakinra for severe forms of COVID-19: a cohort study. The Lancet. Rheumatology. 2020; 2: e393–e400.

[27] Franzetti M, Pozzetti U, Carugati M, Pandolfo A, Molteni C, Faccioli P, et al. Interleukin-1 receptor antagonist anakinra in association with remdesivir in severe COVID-19: a case report. International journal of Infectious Diseases. 2020; 97: 215–218.

[28] Iglesias-Julián E, López-Veloso M, de-la-Torre-Ferrera N, Barraza-Vengoechea JC, Delgado-López PD, Colazo-Burlato M, et al. High dose subcutaneous Anakinra to treat acute respiratory distress syndrome secondary to cytokine storm syndrome among severely ill COVID-19 patients. Journal of Autoimmunity. 2020; 115: 102537.

[29] Kooistra EJ, Waalders NJB, Grondman I, Janssen NAF, de Nooijer AH, Netea MG, et al. Anakinra treatment in critically ill COVID-19 patients: a prospective cohort study. Critical Care. 2020; 24: 688.

[30] Kyriazopoulou E, Panagopoulos P, Metallidis S, Dalekos GN, Poulakou G, Gatselis N, et al. An open label trial of anakinra to prevent respiratory failure in COVID-19. eLife. 2021; 10: e66125.

[31] Monti G, Campochiaro C, Zangrillo A, Scandroglio AM, Fominskiy E, Cavalli G, et al. Immunosuppressive strategies in invasively ventilated ARDS COVID-19 patients. Minerva Anestesiologica. 2021; 87: 891–902.

[32] Derde LPG, Gordon AC, Mouncey PR, Al-Beidh F, Rowan KM, Nichol AD, et al. Effectiveness of tocilizumab, sarilumab, and anakinra for critically ill patients with COVID-19 the REMAP-CAP COVID-19 immune modulation therapy domain randomized clinical trial. medRxiv. 2021; 1–21.

[33] Zantah M, Castillo ED, Gangemi AJ, Patel M, Chowdhury J, Verga S, et al. Anakinra and Intravenous IgG versus Tocilizumab in the Treatment of COVID-19 Pneumonia. medRxiv. 2020; 1–27.

[34] Langer-Gould A, Smith JB, Gonzales EG, Castillo RD, Figueroa JG, Ramanathan A, et al. Early identification of COVID-19 cytokine storm and treatment with anakinra or tocilizumab. International Journal of Infectious Diseases. 2020; 99: 291–297.

[35] Kharazmi AB, Moradi O, Haghighi M, Kouchek M, Manafi-Rasi A, Raoufi M, et al. A randomized controlled clinical trial on efficacy and safety of anakinra in patients with severe COVID-19. Immunity, Inflammation and Disease. 2022; 10: 201–208.

[36] García-García JA, Pérez-Quintana M, Ramos-Giráldez C, Cebrián-González I, Martín-Ponce ML, Del Valle-Villagrán J, et al. Anakinra versus baricitinib: different strategies for patients hospitalized with COVID-19. Journal of Clinical Medicine. 2021; 10: 4019.

[37] Declercq J, Van Damme KFA, De Leeuw E, Maes B, Bosteels C, Tavernier SJ, et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. The Lancet. Respiratory Medicine. 2021; 9: 1427–1438.

[38] Karakike E, Dalekos GN, Koutsodimitropoulos I, Saridaki M, Pourzitaki C, Papathanakos G, et al. ESCAPE: an open-label trial of personalized immunotherapy in critically lll COVID-19 patients. Journal of Innate Immunity. 2022; 14: 218–228.

[39] Kyriazopoulou E, Poulakou G, Milionis H, Metallidis S, Adamis G, Tsiakos K, et al. Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial. Nature Medicine. 2021; 27: 1752–1760.

[40] Aomar-Millán IF, Salvatierra J, Torres-Parejo Ú, Faro-Miguez N, Callejas-Rubio JL, Ceballos-Torres Á, et al. Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID-19 pneumonia and moderate hyperinflammation. A retrospective cohort study. Internal and Emergency Medicine. 2021; 16: 843–852.

[41] Balkhair A, Al-Zakwani I, Al Busaidi M, Al-Khirbash A, Al Mubaihsi S, BaTaher H, et al. Anakinra in hospitalized patients with severe COVID-19 pneumonia requiring oxygen therapy: Results of a prospective, open-label, interventional study. International Journal of Infectious Diseases. 2021; 103: 288–296.

[42] Bozzi G, Mangioni D, Minoia F, Aliberti S, Grasselli G, Barbetta L, et al. Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: an observational cohort study. The Journal of Allergy and Clinical Immunology. 2021; 147: 561–566.

[43] Cauchois R, Koubi M, Delarbre D, Manet C, Carvelli J, Blasco VB, et al. Early IL-1 receptor blockade in severe inflammatory respiratory failure complicating COVID-19. Proceedings of the National Academy of Sciences. 2020; 117: 18951–18953.

[44] Dalekos GN, Stefos A, Georgiadou S, Lygoura V, Michail A, Ntaios G, et al. Lessons from pathophysiology: use of individualized combination treatments with immune interventional agents to tackle severe respiratory failure in patients with COVID-19. European Journal of Internal Medicine. 2021; 88: 52–62.

[45] de la Calle C, López-Medrano F, Pablos JL, Lora-Tamayo J, Maestro-de la Calle G, Sánchez-Fernández M, et al. Effectiveness of anakinra for tocilizumab-refractory severe COVID-19: a single-centre retrospective comparative study. International Journal of Infectious Diseases. 2021; 105: 319–325.

[46] Angus DC, Derde L, Al-Beidh F, Annane D, Arabi Y, Beane A, et al. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial. JAMA. 2020; 324: 1317–1329.

[47] Kyriazopoulou E, Huet T, Cavalli G, Gori A, Kyprianou M, Pickkers P, et al. Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis. The Lancet. Rheumatology. 2021; 3: e690–e697.

[48] van Deuren RC, Arts P, Cavalli G, Jaeger M, Steehouwer M, van de Vorst M, et al. Impact of rare and common genetic variation in the interleukin-1 pathway on human cytokine responses. Genome Medicine. 2021; 13: 94.

[49] McGonagle D, Ramanan AV, Bridgewood C. Immune cartography of macrophage activation syndrome in the COVID-19 era. Nature Reviews. Rheumatology. 2021; 17: 145–157.

[50] Caricchio R, Gallucci M, Dass C, Zhang X, Gallucci S, Fleece D, et al. Preliminary predictive criteria for COVID-19 cytokine storm. Annals of the Rheumatic Diseases. 2021; 80: 88–95.

[51] Kox M, Waalders NJB, Kooistra EJ, Gerretsen J, Pickkers P. Cytokine levels in critically Ill patients with COVID-19 and other conditions. JAMA. 2020; 324: 1565–1567.

[52] Mason RJ. Thoughts on the alveolar phase of COVID-19. American Journal of Physiology-Lung Cellular and Molecular Physiology. 2020; 319: L115–L120.

[53] Jouan Y, Baranek T, Si-Tahar M, Paget C, Guillon A. Lung compart-mentalization of inflammatory biomarkers in COVID-19-related ARDS. Critical Care. 2021; 25: 120.

[54] Cavalli G, Dinarello CA. Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies. Rheumatology. 2015; 54: 2134–2144.

[55] Cavalli G, Foppoli M, Cabrini L, Dinarello CA, Tresoldi M, Dagna L. Interleukin-1 receptor blockade rescues myocarditis-associated end-stage heart failure. Frontiers in Immunology. 2017; 8: 131.

[56] De Luca G, Cavalli G, Campochiaro C, Tresoldi M, Dagna L. Myocardi-tis: an interleukin-1-mediated disease? Frontiers in Immunology. 2018; 9: 1335.

[57] Eloseily EM, Weiser P, Crayne CB, Haines H, Mannion ML, Stoll ML, et al. Benefit of anakinra in treating pediatric secondary hemophagocytic lymphohistiocytosis. Arthritis & Rheumatology. 2020; 72: 326–334.

[58] Ravelli A, Minoia F, Davì S, Horne A, Bovis F, Pistorio A, et al. 2016 classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a european league against rheumatism/american college of rheumatology/paediatric rheumatology international trials organisation collaborative initiative. Arthritis & Rheumatology. 2016; 68: 566–576.

[59] Minoia F, Davì S, Horne A, Demirkaya E, Bovis F, Li C, et al. Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients. Arthritis & Rheumatology. 2014; 66: 3160–3169.

[60] Mehta P, Cron RQ, Hartwell J, Manson JJ, Tattersall RS. Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome. The Lancet Rheumatology. 2020; 2: e358–e367.

[61] Fukaya S, Yasuda S, Hashimoto T, Oku K, Kataoka H, Horita T, et al. Clinical features of haemophagocytic syndrome in patients with systemic autoimmune diseases: analysis of 30 cases. Rheumatology. 2008; 47: 1686–1691.

[62] Cavalli G, Dinarello CA. Anakinra therapy for non-cancer inflammatory diseases. Frontiers in Pharmacology. 2018; 9: 1157.

[63] Tsakiri N, Kimber I, Rothwell NJ, Pinteaux E. Interleukin-1-induced interleukin-6 synthesis is mediated by the neutral sphingomyelinase/Src kinase pathway in neurones. British Journal of Pharmacology. 2008; 153: 775–783.

[64] Rovina N, Akinosoglou K, Eugen-Olsen J, Hayek S, Reiser J, Giamarellos-Bourboulis EJ. Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia. Critical Care. 2020; 24: 187.

[65] Azam TU, Shadid HR, Blakely P, O’Hayer P, Berlin H, Pan M, et al. Soluble urokinase receptor (SuPAR) in COVID-19-related AKI. Journal of the American Society of Nephrology. 2020; 31: 2725–2735.

[66] Cavalli G, Dagna L. The right place for IL-1 inhibition in COVID-19. The Lancet. Respiratory Medicine. 2021; 9: 223–224.

[67] European Medicines Agency. COVID-19 treatments: authorised. 2022. Available at: https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/treatments-covid-19/covid-19-treatments-authorised (Accessed: 18 March 2022).



Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,200 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Chemical Abstracts Service Source Index The CAS Source Index (CASSI) Search Tool is an online resource that can quickly identify or confirm journal titles and abbreviations for publications indexed by CAS since 1907, including serial and non-serial scientific and technical publications.

Index Copernicus The Index Copernicus International (ICI) Journals database’s is an international indexation database of scientific journals. It covered international scientific journals which divided into general information, contents of individual issues, detailed bibliography (references) sections for every publication, as well as full texts of publications in the form of attached files (optional). For now, there are more than 58,000 scientific journals registered at ICI.

Geneva Foundation for Medical Education and Research The Geneva Foundation for Medical Education and Research (GFMER) is a non-profit organization established in 2002 and it works in close collaboration with the World Health Organization (WHO). The overall objectives of the Foundation are to promote and develop health education and research programs.

Scopus: CiteScore 0.5(2021) Scopus is Elsevier's abstract and citation database launched in 2004. Scopus covers nearly 36,377 titles (22,794 active titles and 13,583 Inactive titles) from approximately 11,678 publishers, of which 34,346 are peer-reviewed journals in top-level subject fields: life sciences, social sciences, physical sciences and health sciences.

Embase Embase (often styled EMBASE for Excerpta Medica dataBASE), produced by Elsevier, is a biomedical and pharmacological database of published literature designed to support information managers and pharmacovigilance in complying with the regulatory requirements of a licensed drug.

Submission Turnaround Time

Conferences

Top